1
|
Dinić S, Arambašić Jovanović J, Uskoković A, Jovanović A, Grdović N, Rajić J, Đorđević M, Sarić A, Bugarski B, Vidaković M, Mihailović M. Liposome Encapsulation Enhances the Antidiabetic Efficacy of Silibinin. Pharmaceutics 2024; 16:801. [PMID: 38931922 DOI: 10.3390/pharmaceutics16060801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2024] [Revised: 06/05/2024] [Accepted: 06/07/2024] [Indexed: 06/28/2024] Open
Abstract
Silibinin has considerable therapeutic potential for the treatment of diabetes through anti-inflammatory, antioxidant, and immunomodulatory properties. However, the therapeutic application of silibinin is quite limited due to its poor bioavailability. In the present study, an attempt was made to improve the antidiabetic efficacy of silibinin by its encapsulation in liposomal vesicles. The liposomes with a high encapsulation efficiency of silibinin (96%) and a zeta potential of -26.2 ± 0.6 mV were developed and studied using nicotinamide/streptozotocin-induced diabetic rats. Administration of silibinin-loaded liposomes to diabetic rats lowered glucose levels, increased insulin levels, and improved pancreatic islet architecture. The anti-inflammatory effect of silibinin-loaded liposomes was demonstrated by a decrease in serum C-reactive protein (CRP) levels and a reduced deposition of collagen fibers in the islets of diabetic rats. Furthermore, silibinin-loaded liposomes were more efficient in lowering glucose, alanine transaminase, triglyceride, and creatinine levels in diabetic rats than pure silibinin. In addition, silibinin-loaded liposomes had a significantly better effect on beta-cell mass and Glut2 glucose receptor distribution in diabetic islets than pure silibinin. The present results clearly show that liposome encapsulation of silibinin enhances its antidiabetic efficacy, which may contribute to the therapeutic benefit of silibinin in the treatment of diabetes and its complications.
Collapse
Affiliation(s)
- Svetlana Dinić
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| | - Jelena Arambašić Jovanović
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| | - Aleksandra Uskoković
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| | - Aleksandra Jovanović
- Institute for the Application of Nuclear Energy INEP, University of Belgrade, 11080 Belgrade, Serbia
| | - Nevena Grdović
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| | - Jovana Rajić
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| | - Marija Đorđević
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| | - Ana Sarić
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| | - Branko Bugarski
- Faculty of Technology and Metallurgy, University of Belgrade, 11000 Belgrade, Serbia
| | - Melita Vidaković
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| | - Mirjana Mihailović
- Department of Molecular Biology, Institute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia
| |
Collapse
|
2
|
Liu D, Wang L, Li H, Li D, Zhou J, Wang J, Zhang Q, Cai D. Co-Delivery of Gemcitabine and Honokiol by Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhances Pancreatic Cancer Therapy via Targeting Depletion of Tumor Stroma. Molecules 2024; 29:675. [PMID: 38338418 PMCID: PMC10856273 DOI: 10.3390/molecules29030675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 01/29/2024] [Accepted: 01/30/2024] [Indexed: 02/12/2024] Open
Abstract
Syndecan-1 (SDC1) modified lipid bilayer (LB)-coated mesoporous silica nanoparticles (MSN) to co-deliver gemcitabine (GEM) and honokiol (HNK) were prepared for the targeting treatment of pancreatic cancer. The encapsulation efficiencies of GEM and HNK in SDC1-LB-MSN-GEM/HNK were determined to be 60.3 ± 3.2% and 73.0 ± 1.1%. The targeting efficiency of SDC1-LB-MSN-GEM/HNK was investigated in BxPC-3 cells in vitro. The fluorescence intensity in the cells treated with SDC1-LB-MSN-Cou6 was 2-fold of LB-MSN-Cou6-treated cells, which was caused by SDC1/IGF1R-mediated endocytosis. As anticipated, its cytotoxicity was significantly increased. Furthermore, the mechanism was verified that SDC1-LB-MSN-HNK induced tumor cell apoptosis through the mitochondrial apoptosis pathway. Finally, the biodistribution, tumor growth inhibition, and preliminary safety studies were performed on BALB/c nude mice bearing BxPC-3 tumor models. The tumor growth inhibition index of SDC1-LB-MSN-GEM/HNK was 56.19%, which was 1.45-fold and 1.33-fold higher than that of the free GEM/HNK and LB-MSN-GEM/HNK treatment groups, respectively. As a result, SDC1-LB-MSN-GEM/HNK combined advantages of both GEM and HNK and simultaneously targeted and eliminated pancreatic cancerous and cancer-associated stromal cells. In summary, the present study demonstrated a new strategy of synergistic GEM and HNK to enhance the therapeutic effect of pancreatic cancer via the targeting depletion of tumor stroma.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Qi Zhang
- Institute of Medicine and Drug Research, Qiqihar Medical University, Qiqihar 161006, China; (D.L.); (L.W.); (H.L.); (D.L.); (J.Z.); (J.W.)
| | - Defu Cai
- Institute of Medicine and Drug Research, Qiqihar Medical University, Qiqihar 161006, China; (D.L.); (L.W.); (H.L.); (D.L.); (J.Z.); (J.W.)
| |
Collapse
|
3
|
Han Z, MacCuaig WM, Gurcan MN, Claros-Sorto J, Garwe T, Henson C, Holter-Chakrabarty J, Hannafon B, Chandra V, Wellberg E, McNally LR. Dynamic 2-deoxy-D-glucose-enhanced multispectral optoacoustic tomography for assessing metabolism and vascular hemodynamics of breast cancer. PHOTOACOUSTICS 2023; 32:100531. [PMID: 37485041 PMCID: PMC10362308 DOI: 10.1016/j.pacs.2023.100531] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 06/22/2023] [Accepted: 07/08/2023] [Indexed: 07/25/2023]
Abstract
Clinical tools for measuring tumor vascular hemodynamics, such as dynamic contrast-enhanced MRI, are clinically important to assess tumor properties. Here we explored the use of multispectral optoacoustic tomography (MSOT), which has a high spatial and temporal resolution, to measure the intratumoral pharmacokinetics of a near-infrared-dye-labeled 2-Deoxyglucose, 2-DG-800, in orthotropic 2-LMP breast tumors in mice. As uptake of 2-DG-800 is dependent on both vascular properties, and glucose transporter activity - a widely-used surrogate for metabolism, we evaluate hemodynamics of 2-DG-MP by fitting the dynamic MSOT signal of 2-DG-800 into two-compartment models including the extended Tofts model (ETM) and reference region model (RRM). We showed that dynamic 2-DG-enhanced MSOT (DGE-MSOT) is powerful in acquiring hemodynamic rate constants, including Ktrans and Kep, via systemically injecting a low dose of 2-DG-800 (0.5 µmol/kg b.w.). In our study, both ETM and RRM are efficient in deriving hemodynamic parameters in the tumor. Area-under-curve (AUC) values (which correlate to metabolism), and Ktrans and Kep values, can effectively distinguish tumor from muscle. Hemodynamic parameters also demonstrated correlations to hemoglobin, oxyhemoglobin, and blood oxygen level (SO2) measurements by spectral unmixing of the MSOT data. Together, our study for the first time demonstrated the capability of DGE-MSOT in assessing vascular hemodynamics of tumors.
Collapse
Affiliation(s)
- Zheng Han
- Department of Surgery, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
- Center for Health Systems Innovation, Oklahoma State University, Stillwater, OK 74078, USA
| | - William M. MacCuaig
- Department of Surgery, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
- Department of Bioengineering, University of Oklahoma, Norman, OK 73019, USA
| | - Metin N. Gurcan
- Center for Biomedical Informatics, Wake Forest Baptist Health, Winston-Salem, NC 27101, USA
| | - Juan Claros-Sorto
- Department of Surgery, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
| | - Tabitha Garwe
- Department of Biostatistics and Epidemiology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
| | - Christina Henson
- Department of Internal Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
| | | | - Bethany Hannafon
- Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
| | - Vishal Chandra
- Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
| | - Elizabeth Wellberg
- Department of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
| | - Lacey R. McNally
- Department of Surgery, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA
| |
Collapse
|
4
|
Samykutty A, Thomas KN, McNally M, Hagood J, Chiba A, Thomas A, McWilliams L, Behkam B, Zhan Y, Council-Troche M, Claros-Sorto JC, Henson C, Garwe T, Sarwar Z, Grizzle WE, McNally LR. Simultaneous Detection of Multiple Tumor-targeted Gold Nanoparticles in HER2-Positive Breast Tumors Using Optoacoustic Imaging. Radiol Imaging Cancer 2023; 5:e220180. [PMID: 37233208 PMCID: PMC10240250 DOI: 10.1148/rycan.220180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 04/12/2023] [Accepted: 04/26/2023] [Indexed: 05/27/2023]
Abstract
Purpose To develop optoacoustic, spectrally distinct, actively targeted gold nanoparticle-based near-infrared probes (trastuzumab [TRA], TRA-Aurelia-1, and TRA-Aurelia-2) that can be individually identifiable at multispectral optoacoustic tomography (MSOT) of human epidermal growth factor receptor 2 (HER2)-positive breast tumors. Materials and Methods Gold nanoparticle-based near-infrared probes (Aurelia-1 and 2) that are optoacoustically active and spectrally distinct for simultaneous MSOT imaging were synthesized and conjugated to TRA to produce TRA-Aurelia-1 and 2. Freshly resected human HER2-positive (n = 6) and HER2-negative (n = 6) triple-negative breast cancer tumors were treated with TRA-Aurelia-1 and TRA-Aurelia-2 for 2 hours and imaged with MSOT. HER2-expressing DY36T2Q cells and HER2-negative MDA-MB-231 cells were implanted orthotopically into mice (n = 5). MSOT imaging was performed 6 hours following the injection, and the Friedman test was used for analysis. Results TRA-Aurelia-1 (absorption peak, 780 nm) and TRA-Aurelia-2 (absorption peak, 720 nm) were spectrally distinct. HER2-positive human breast tumors exhibited a significant increase in optoacoustic signal following TRA-Aurelia-1 (28.8-fold) or 2 (29.5-fold) (P = .002) treatment relative to HER2-negative tumors. Treatment with TRA-Aurelia-1 and 2 increased optoacoustic signals in DY36T2Q tumors relative to those in MDA-MB-231 controls (14.8-fold, P < .001; 20.8-fold, P < .001, respectively). Conclusion The study demonstrates that TRA-Aurelia 1 and 2 nanoparticles operate as a spectrally distinct HER2 breast tumor-targeted in vivo optoacoustic agent. Keywords: Molecular Imaging, Nanoparticles, Photoacoustic Imaging, Breast Cancer Supplemental material is available for this article. © RSNA, 2023.
Collapse
Affiliation(s)
- Abhilash Samykutty
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Karl N. Thomas
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Molly McNally
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Jordan Hagood
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Akiko Chiba
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Alexandra Thomas
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Libby McWilliams
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Bahareh Behkam
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Ying Zhan
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - McAlister Council-Troche
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Juan C. Claros-Sorto
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Christina Henson
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Tabitha Garwe
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Zoona Sarwar
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - William E. Grizzle
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| | - Lacey R. McNally
- From the Department of Surgery, Stephenson Comprehensive Cancer
Center, University of Oklahoma, Oklahoma City, Okla (A.S., M.M., J.H., L.M.,
J.C.C.S.); Department of Radiation Oncology, University of Oklahoma Health
Science Center, Oklahoma City, Okla (C.H.); Atrium Wake Forest Health
Comprehensive Cancer Center, Winston-Salem, NC (A.T., L.M.); Department of
Surgery, Duke University, Durham, NC (A.C.); Department of Cancer Biology, Wake
Forest School of Medicine, Winston-Salem, NC 27013 (A.S., K.N.T., M.M., L.R.M.);
Department of Mechanical Engineering, Virginia Tech University, Blacksburg, Va
(B.B., Y.Z., M.C.T.); and Department of Epidemiology and Biostatistics (T.G.,
Z.S.) and Department of Pathology (W.E.G.), University of Alabama at Birmingham,
Birmingham, Ala
| |
Collapse
|
5
|
Chen Y, Nozdriukhin D, Michel-Souzy S, Padberg C, Wurm FR, Razansky D, Deán-Ben XL, Koshkina O. Biobased Agents for Single-Particle Detection with Optoacoustics. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2023:e2207199. [PMID: 37021720 DOI: 10.1002/smll.202207199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 02/28/2023] [Indexed: 06/19/2023]
Abstract
Optoacoustic (OA, photoacoustic) imaging synergistically combines rich optical contrast with the resolution of ultrasound within light-scattering biological tissues. Contrast agents have become essential to boost deep-tissue OA sensitivity and fully exploit the capabilities of state-of-the-art OA imaging systems, thus facilitating the clinical translation of this modality. Inorganic particles with sizes of several microns can also be individually localized and tracked, thus enabling new applications in drug delivery, microrobotics, or super-resolution imaging. However, significant concerns have been raised regarding the low bio-degradability and potential toxic effects of inorganic particles. Bio-based, biodegradable nano- and microcapsules consisting of an aqueous core with clinically-approved indocyanine green (ICG) and a cross-linked casein shell obtained in an inverse emulsion approach are introduced. The feasibility to provide contrast-enhanced in vivo OA imaging with nanocapsules as well as localizing and tracking individual larger microcapsules of 4-5 µm is demonstrated. All components of the developed capsules are safe for human use and the inverse emulsion approach is known to be compatible with a variety of shell materials and payloads. Hence, the enhanced OA imaging performance can be exploited in multiple biomedical studies and can open a route to clinical approval of agents detectable at a single-particle level.
Collapse
Affiliation(s)
- Yunbo Chen
- Sustainable Polymer Chemistry, Department of Molecules and Materials, Mesa+ Institute for Nanotechnology, Faculty of Science and Technology, University of Twente, Drienerlolaan 5, Enschede, 7522NB, The Netherlands
- Key Lab of Science and Technology of Eco-Textile, Ministry of Education, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, P. R. China
| | - Daniil Nozdriukhin
- Institute for Biomedical Engineering and Institute of Pharmacology and Toxicology, Faculty of Medicine, University of Zürich, Winterturenstraße 190, Zürich, 8057, Switzerland
- Institute for Biomedical Engineering, Department of Information Technology and Electrical Engineering, ETH Zürich, Wolfgang-Pauli-Str. 27, Zürich, 8093, Switzerland
| | - Sandra Michel-Souzy
- Biomolecular Nanotechnology, Department of Molecules and Materials, Mesa+ Institute for Nanotechnology, Faculty of Science and Technology University of Twente, Drienerlolaan 5, Enschede, 7522NB, The Netherlands
| | - Clemens Padberg
- Sustainable Polymer Chemistry, Department of Molecules and Materials, Mesa+ Institute for Nanotechnology, Faculty of Science and Technology, University of Twente, Drienerlolaan 5, Enschede, 7522NB, The Netherlands
| | - Frederik R Wurm
- Sustainable Polymer Chemistry, Department of Molecules and Materials, Mesa+ Institute for Nanotechnology, Faculty of Science and Technology, University of Twente, Drienerlolaan 5, Enschede, 7522NB, The Netherlands
| | - Daniel Razansky
- Institute for Biomedical Engineering and Institute of Pharmacology and Toxicology, Faculty of Medicine, University of Zürich, Winterturenstraße 190, Zürich, 8057, Switzerland
- Institute for Biomedical Engineering, Department of Information Technology and Electrical Engineering, ETH Zürich, Wolfgang-Pauli-Str. 27, Zürich, 8093, Switzerland
| | - Xosé Luís Deán-Ben
- Institute for Biomedical Engineering and Institute of Pharmacology and Toxicology, Faculty of Medicine, University of Zürich, Winterturenstraße 190, Zürich, 8057, Switzerland
- Institute for Biomedical Engineering, Department of Information Technology and Electrical Engineering, ETH Zürich, Wolfgang-Pauli-Str. 27, Zürich, 8093, Switzerland
| | - Olga Koshkina
- Sustainable Polymer Chemistry, Department of Molecules and Materials, Mesa+ Institute for Nanotechnology, Faculty of Science and Technology, University of Twente, Drienerlolaan 5, Enschede, 7522NB, The Netherlands
| |
Collapse
|
6
|
Zhu L, Mao H, Yang L. Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2022; 14:e1793. [PMID: 35396932 PMCID: PMC9373845 DOI: 10.1002/wnan.1793] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/01/2022] [Revised: 02/22/2022] [Accepted: 03/10/2022] [Indexed: 06/14/2023]
Abstract
Despite current advances in new approaches for cancer detection and treatment, pancreatic cancer remains one of the most lethal cancer types. Difficult to detect early, aggressive tumor biology, and resistance to chemotherapy, radiotherapy, and immunotherapy result in a poor prognosis of pancreatic cancer patients with a 5-year survival of 10%. With advances in cancer nanotechnology, new imaging and drug delivery approaches that allow the development of multifunctional nanotheranostic agents offer opportunities for improving pancreatic cancer treatment using precision oncology. In this review, we will introduce potential applications of innovative theranostic strategies to address major challenges in the treatment of pancreatic cancer at different disease stages. Several important issues concerning targeted delivery of theranostic nanoparticles and tumor stromal barriers are discussed. We then focus on the development of a magnetic iron oxide nanoparticle platform for multimodal therapy of pancreatic cancer, including MRI monitoring targeted nanoparticle/drug delivery, therapeutic response, and tumor re-staging, activation of tumor immune response by immunoactivating nanoparticle and magnetic hyperthermia therapy, and intraoperative interventions for improving the outcome of targeted therapy. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > In Vivo Nanodiagnostics and Imaging.
Collapse
Affiliation(s)
- Lei Zhu
- Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Hui Mao
- Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
- Winship Cancer Institute, Atlanta, Georgia, USA
| | - Lily Yang
- Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
- Winship Cancer Institute, Atlanta, Georgia, USA
| |
Collapse
|
7
|
Andreou C, Weissleder R, Kircher MF. Multiplexed imaging in oncology. Nat Biomed Eng 2022; 6:527-540. [PMID: 35624151 DOI: 10.1038/s41551-022-00891-5] [Citation(s) in RCA: 37] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 09/06/2021] [Indexed: 01/24/2023]
Abstract
In oncology, technologies for clinical molecular imaging are used to diagnose patients, establish the efficacy of treatments and monitor the recurrence of disease. Multiplexed methods increase the number of disease-specific biomarkers that can be detected simultaneously, such as the overexpression of oncogenic proteins, aberrant metabolite uptake and anomalous blood perfusion. The quantitative localization of each biomarker could considerably increase the specificity and the accuracy of technologies for clinical molecular imaging to facilitate granular diagnoses, patient stratification and earlier assessments of the responses to administered therapeutics. In this Review, we discuss established techniques for multiplexed imaging and the most promising emerging multiplexing technologies applied to the imaging of isolated tissues and cells and to non-invasive whole-body imaging. We also highlight advances in radiology that have been made possible by multiplexed imaging.
Collapse
Affiliation(s)
- Chrysafis Andreou
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Department of Electrical and Computer Engineering, University of Cyprus, Nicosia, Cyprus
| | - Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. .,Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. .,Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
| | - Moritz F Kircher
- Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA.,Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
8
|
Li X, Ge J, Zhang S, Wu J, Qi L, Chen W. Multispectral interlaced sparse sampling photoacoustic tomography based on directional total variation. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2022; 214:106562. [PMID: 34906784 DOI: 10.1016/j.cmpb.2021.106562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 11/11/2021] [Accepted: 11/26/2021] [Indexed: 06/14/2023]
Abstract
BACKGROUND AND OBJECTIVE Photoacoustic tomography (PAT) is capable of obtaining cross-sectional images of small animals that represent the optical absorption of biological tissues. The multispectral Interlaced Sparse Sampling PAT, or ISS-PAT, is a previously proposed PAT imaging method that offered high quality images with much sparser transducer angular coverage. Although it provides superior imaging performance, the original ISS-PAT method suffered from a heavy computation burden, which hinders its practical application. METHODS Here, we propose a new regularization scheme based on the directional total variation (dTV) for ISS-PAT. This method efficiently imposes the structural information by considering both the edge position and direction information of the anatomical prior image in ISS-PAT. It does not require image segmentation, and can be conveniently solved by a modified alternating direction of multipliers (ADMM) algorithm. RESULTS We perform simulation, tissue mimicking phantom and in vivo small animal experiments to evaluate the proposed scheme. The reconstructed PAT images showed image quality and spectral un-mixing accuracy close to those obtained by non-local means based ISS-PAT, but with much shorter image reconstruction time. For a 1/6 sparse sampling rate, the average efficiency improvement is nearly 16-folds. CONCLUSIONS The experimental results demonstrate the feasibility of the dTV regularization scheme for ISS-PAT. Its efficient image reconstruction performance facilitates the potential of the hardware realization and practical applications of the ISS-PAT.
Collapse
Affiliation(s)
- Xipan Li
- School of Biomedical Engineering, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, Guangdong, 510515, China; Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, China
| | - Jia Ge
- School of Biomedical Engineering, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, Guangdong, 510515, China
| | - Shuangyang Zhang
- School of Biomedical Engineering, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, Guangdong, 510515, China
| | - Jian Wu
- School of Biomedical Engineering, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, Guangdong, 510515, China
| | - Li Qi
- School of Biomedical Engineering, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, Guangdong, 510515, China.
| | - Wufan Chen
- School of Biomedical Engineering, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, Guangdong, 510515, China.
| |
Collapse
|
9
|
Exogenous Contrast Agents in Photoacoustic Imaging: An In Vivo Review for Tumor Imaging. NANOMATERIALS 2022; 12:nano12030393. [PMID: 35159738 PMCID: PMC8840344 DOI: 10.3390/nano12030393] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 01/10/2022] [Accepted: 01/18/2022] [Indexed: 11/16/2022]
Abstract
The field of cancer theranostics has grown rapidly in the past decade and innovative ‘biosmart’ theranostic materials are being synthesized and studied to combat the fast growth of cancer metastases. While current state-of-the-art oncology imaging techniques have decreased mortality rates, patients still face a diminished quality of life due to treatment. Therefore, improved diagnostics are needed to define in vivo tumor growths on a molecular level to achieve image-guided therapies and tailored dosage needs. This review summarizes in vivo studies that utilize contrast agents within the field of photoacoustic imaging—a relatively new imaging modality—for tumor detection, with a special focus on imaging and transducer parameters. This paper also details the different types of contrast agents used in this novel diagnostic field, i.e., organic-based, metal/inorganic-based, and dye-based contrast agents. We conclude this review by discussing the challenges and future direction of photoacoustic imaging.
Collapse
|
10
|
MacCuaig WM, Fouts BL, McNally MW, Grizzle WE, Chuong P, Samykutty A, Mukherjee P, Li M, Jasinski J, Behkam B, McNally LR. Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. ACS APPLIED MATERIALS & INTERFACES 2021; 13:49614-49630. [PMID: 34653338 PMCID: PMC9783196 DOI: 10.1021/acsami.1c09379] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Nanoparticles are widely studied as theranostic vehicles for cancer; however, clinical translation has been limited due to poor tumor specificity. Features that maximize tumor uptake remain controversial, particularly when using clinically relevant models. We report a systematic study that assesses two major features for the impact on tumor specificity, i.e., active vs passive targeting and nanoparticle size, to evaluate relative influences in vivo. Active targeting via the V7 peptide is superior to passive targeting for uptake by pancreatic tumors, irrespective of nanoparticle size, observed through in vivo imaging. Size has a secondary effect on uptake for actively targeted nanoparticles in which 26 nm nanoparticles outperform larger 45 and 73 nm nanoparticles. Nanoparticle size had no significant effect on uptake for passively targeted nanoparticles. Results highlight the superiority of active targeting over nanoparticle size for tumor uptake. These findings suggest a framework for optimizing similar nonaggregate nanoparticles for theranostic treatment of recalcitrant cancers.
Collapse
Affiliation(s)
- William M. MacCuaig
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Benjamin L. Fouts
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
| | - Molly W McNally
- Department of Surgery, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157, USA
| | - William E. Grizzle
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Phillip Chuong
- Department of Surgery, University of Louisville, Louisville, KY 40202, USA
| | - Abhilash Samykutty
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157, USA
| | | | - Min Li
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
| | - Jacek Jasinski
- Conn Center Materials Characterization, University of Louisville, Louisville, KY 40202, USA
| | - Bahareh Behkam
- Department of Mechanical Engineering, Virginia Tech, Blacksburg, VA, 24061, USA
| | - Lacey R. McNally
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Surgery, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157, USA
| |
Collapse
|
11
|
Laramie MD, Fouts BL, MacCuaig WM, Buabeng E, Jones MA, Mukherjee P, Behkam B, McNally LR, Henary M. Improved pentamethine cyanine nanosensors for optoacoustic imaging of pancreatic cancer. Sci Rep 2021; 11:4366. [PMID: 33623069 PMCID: PMC7902650 DOI: 10.1038/s41598-021-83658-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Accepted: 01/08/2021] [Indexed: 01/31/2023] Open
Abstract
Optoacoustic imaging is a new biomedical imaging technology with clear benefits over traditional optical imaging and ultrasound. While the imaging technology has improved since its initial development, the creation of dedicated contrast agents for optoacoustic imaging has been stagnant. Current exploration of contrast agents has been limited to standard commercial dyes that have already been established in optical imaging applications. While some of these compounds have demonstrated utility in optoacoustic imaging, they are far from optimal and there is a need for contrast agents with tailored optoacoustic properties. The synthesis, encapsulation within tumor targeting silica nanoparticles and applications in in vivo tumor imaging of optoacoustic contrast agents are reported.
Collapse
Affiliation(s)
- Matthew D Laramie
- Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA
| | - Benjamin L Fouts
- Department of Surgery, Oklahoma Health Science Center, Oklahoma City, 73104, USA
- Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, OK, 73104, USA
| | - William M MacCuaig
- Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, OK, 73104, USA
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK, 72073, USA
| | - Emmanuel Buabeng
- Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA
- Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, 30303, USA
| | - Meredith A Jones
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK, 72073, USA
| | - Priyabrata Mukherjee
- Department of Pathology, Oklahoma Health Science Center, Oklahoma City, OK, 73104, USA
| | - Bahareh Behkam
- Department of Mechanical Engineering, Virginia Tech University, Blacksburg, VA, 24061, USA
| | - Lacey R McNally
- Department of Surgery, Oklahoma Health Science Center, Oklahoma City, 73104, USA.
- Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, OK, 73104, USA.
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK, 72073, USA.
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC, 27157, USA.
| | - Maged Henary
- Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA.
- Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, 30303, USA.
| |
Collapse
|
12
|
Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo. Cancers (Basel) 2020; 12:cancers12082279. [PMID: 32823919 PMCID: PMC7464900 DOI: 10.3390/cancers12082279] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 08/01/2020] [Accepted: 08/03/2020] [Indexed: 02/07/2023] Open
Abstract
Pancreatic cancer remains a recalcitrant neoplasm associated with chemoresistance and high fatality. Because it is frequently resistant to apoptosis, exploiting autophagic cell death could offer a new treatment approach. We repurpose echinomycin, an antibiotic encapsulated within a syndecan-1 actively targeted nanoparticle, for treatment of pancreatic cancer. Tumor-specific uptake, biodistribution, efficacy of nanodelivered echinomycin, and mechanism of cell death were assessed in aggressive, metastatic models of pancreatic cancer. In these autophagic-dependent pancreatic cancer models, echinomycin treatment resulted in autophagic cell death noted by high levels of LC3 among other autophagy markers, but without hallmarks of apoptosis, e.g., caspase activation and chromatin fragmentation, or necrosis, e.g., plasma membrane degradation and chromatin condensation/degrading. In vivo, biodistribution of syndecan-1-targeted nanoparticles indicated preferential S2VP10 or S2CP9 tumor uptake compared to the liver and kidney (S2VP10 p = 0.0016, p = 0.00004 and S2CP9 p = 0.0009, p = 0.0001). Actively targeted nanodelivered echinomycin resulted in significant survival increases compared to Gemzar (S2VP10 p = 0.0003, S2CP9 p = 0.0017) or echinomycin only (S2VP10 p = 0.0096, S2CP9 p = 0.0073). We demonstrate that actively targeted nanodelivery of echinomycin results in autophagic cell death in pancreatic and potentially other high-autophagy, apoptosis-resistant tumors. Collectively, these findings support syndecan-1-targeted delivery of echinomycin and dysregulation of autophagy to induce cell death in pancreatic cancer.
Collapse
|
13
|
Garza-Morales R, Rendon BE, Malik MT, Garza-Cabrales JE, Aucouturier A, Bermúdez-Humarán LG, McMasters KM, McNally LR, Gomez-Gutierrez JG. Targeting Melanoma Hypoxia with the Food-Grade Lactic Acid Bacterium Lactococcus Lactis. Cancers (Basel) 2020; 12:cancers12020438. [PMID: 32069844 PMCID: PMC7072195 DOI: 10.3390/cancers12020438] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Revised: 02/07/2020] [Accepted: 02/10/2020] [Indexed: 12/12/2022] Open
Abstract
Melanoma is the most aggressive form of skin cancer. Hypoxia is a feature of the tumor microenvironment that reduces efficacy of immuno- and chemotherapies, resulting in poor clinical outcomes. Lactococcus lactis is a facultative anaerobic gram-positive lactic acid bacterium (LAB) that is Generally Recognized as Safe (GRAS). Recently, the use of LAB as a delivery vehicle has emerged as an alternative strategy to deliver therapeutic molecules; therefore, we investigated whether L. lactis can target and localize within melanoma hypoxic niches. To simulate hypoxic conditions in vitro, melanoma cells A2058, A375 and MeWo were cultured in a chamber with a gas mixture of 5% CO2, 94% N2 and 1% O2. Among the cell lines tested, MeWo cells displayed greater survival rates when compared to A2058 and A375 cells. Co-cultures of L. lactis expressing GFP or mCherry and MeWo cells revealed that L. lactis efficiently express the transgenes under hypoxic conditions. Moreover, multispectral optoacoustic tomography (MSOT), and near infrared (NIR) imaging of tumor-bearing BALB/c mice revealed that the intravenous injection of either L. lactis expressing β-galactosidase (β-gal) or infrared fluorescent protein (IRFP713) results in the establishment of the recombinant bacteria within tumor hypoxic niches. Overall, our data suggest that L. lactis represents an alternative strategy to target and deliver therapeutic molecules into the tumor hypoxic microenvironment.
Collapse
Affiliation(s)
- Rodolfo Garza-Morales
- Department of Surgery, School of Medicine, University of Louisville, Louisville, KY 40202, USA; (R.G.-M.); (J.E.G.-C.); (K.M.M.)
| | - Beatriz E. Rendon
- Molecular Targets Program, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA;
| | - Mohammad Tariq Malik
- Department of Microbiology, School of Medicine, University of Louisville, Louisville, KY 40202, USA;
| | - Jeannete E. Garza-Cabrales
- Department of Surgery, School of Medicine, University of Louisville, Louisville, KY 40202, USA; (R.G.-M.); (J.E.G.-C.); (K.M.M.)
| | - Anne Aucouturier
- INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, 78350 Jouy-en-Josas, France; (A.A.); (L.G.B.-H.)
| | - Luis G. Bermúdez-Humarán
- INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, 78350 Jouy-en-Josas, France; (A.A.); (L.G.B.-H.)
| | - Kelly M. McMasters
- Department of Surgery, School of Medicine, University of Louisville, Louisville, KY 40202, USA; (R.G.-M.); (J.E.G.-C.); (K.M.M.)
| | - Lacey R. McNally
- Department of Bioengineering, Stephenson Cancer Center, University of Oklahoma, Norman, OK 73019, USA;
| | - Jorge G. Gomez-Gutierrez
- Department of Surgery, School of Medicine, University of Louisville, Louisville, KY 40202, USA; (R.G.-M.); (J.E.G.-C.); (K.M.M.)
- Correspondence: ; Tel.: +1-(502)-852-5745
| |
Collapse
|
14
|
Jia Y, Wang C, Zheng J, Lin G, Ni D, Shen Z, Huang B, Li Y, Guan J, Hong W, Chen Y, Wu R. Novel nanomedicine with a chemical-exchange saturation transfer effect for breast cancer treatment in vivo. J Nanobiotechnology 2019; 17:123. [PMID: 31847857 PMCID: PMC6918642 DOI: 10.1186/s12951-019-0557-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Accepted: 12/10/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Nanomedicine is a promising new approach to cancer treatment that avoids the disadvantages of traditional chemotherapy and improves therapeutic indices. However, the lack of a real-time visualization imaging technology to monitor drug distribution greatly limits its clinical application. Image-tracked drug delivery is of great clinical interest; it is useful for identifying those patients for whom the therapy is more likely to be beneficial. This paper discusses a novel nanomedicine that displays features of nanoparticles and facilitates functional magnetic resonance imaging but is challenging to prepare. RESULTS To achieve this goal, we synthesized an acylamino-containing amphiphilic block copolymer (polyethylene glycol-polyacrylamide-polyacetonitrile, PEG-b-P(AM-co-AN)) by reversible addition-fragmentation chain transfer (RAFT) polymerization. The PEG-b-P(AM-co-AN) has chemical exchange saturation transfer (CEST) effects, which enable the use of CEST imaging for monitoring nanocarrier accumulation and providing molecular information of pathological tissues. Based on PEG-b-P(AM-co-AN), a new nanomedicine PEG-PAM-PAN@DOX was constructed by nano-precipitation. The self-assembling nature of PEG-PAM-PAN@DOX made the synthesis effective, straightforward, and biocompatible. In vitro studies demonstrate decreased cytotoxicity of PEG-PAM-PAN@DOX compared to free doxorubicin (half-maximal inhibitory concentration (IC50), mean ~ 0.62 μg/mL vs. ~ 5 μg/mL), and the nanomedicine more efficiently entered the cytoplasm and nucleus of cancer cells to kill them. Further, in vivo animal experiments showed that the nanomedicine developed was not only effective against breast cancer, but also displayed an excellent sensitive CEST effect for monitoring drug accumulation (at about 0.5 ppm) in tumor areas. The CEST signal of post-injection 2 h was significantly higher than that of pre-injection (2.17 ± 0.88% vs. 0. 09 ± 0.75%, p < 0.01). CONCLUSIONS The nanomedicine with CEST imaging reflects the characterization of tumors and therapeutic functions has great potential medical applications.
Collapse
Affiliation(s)
- Yanlong Jia
- Department of Radiology, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China
| | - Chaochao Wang
- Shanghai Key Laboratory of Advanced Polymeric Materials, School of Chemistry and Molecular Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai, 200237, People's Republic of China
| | - Jiehua Zheng
- Department of General Surgery, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China
| | - Guisen Lin
- Department of Radiology, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China
| | - Dalong Ni
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Zhiwei Shen
- Department of Radiology, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China
| | - Baoxuan Huang
- Shanghai Key Laboratory of Advanced Polymeric Materials, School of Chemistry and Molecular Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai, 200237, People's Republic of China
| | - Yan Li
- Department of Radiology, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China
| | - Jitian Guan
- Department of Radiology, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China
| | - Weida Hong
- Department of General Surgery, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China
| | - Yuanfeng Chen
- Department of Radiology, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China
| | - Renhua Wu
- Department of Radiology, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China.
| |
Collapse
|
15
|
Optoacoustic imaging in gastroenterology. TRANSLATIONAL BIOPHOTONICS 2019. [DOI: 10.1002/tbio.201900002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
16
|
Napp J, Stammes MA, Claussen J, Prevoo HA, Sier CF, Hoeben FJ, Robillard MS, Vahrmeijer AL, Devling T, Chan AB, de Geus-Oei LF, Alves F. Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma. Int J Cancer 2018; 142:2118-2129. [DOI: 10.1002/ijc.31236] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 12/04/2017] [Accepted: 12/14/2017] [Indexed: 01/30/2023]
Affiliation(s)
- Joanna Napp
- Institute of Interventional and Diagnostic Radiology, University Medical Center Göttingen; Göttingen Lower Saxony Germany
- Clinic of Haematology and Medical Oncology; University Medical Center Göttingen; Göttingen Lower Saxony Germany
- Translational Molecular Imaging, Max-Planck-Institute of Experimental Medicine; Göttingen Lower Saxony Germany
| | - Marieke A. Stammes
- Percuros B.V., AE Enschede; The Netherlands
- Department of Radiology; Leiden University Medical Center; RC Leiden The Netherlands
| | - Jing Claussen
- iThera Medical GmbH, Zielstattstrasse; Munich Germany
| | | | | | | | - Marc S. Robillard
- Tagworks Pharmaceuticals, Geert Grooteplein Zuid 10; GA Nijmegen The Netherlands
| | | | - Tim Devling
- iThera Medical GmbH, Zielstattstrasse; Munich Germany
| | | | - Lioe-Fee de Geus-Oei
- Department of Radiology; Leiden University Medical Center; RC Leiden The Netherlands
- Biomedical Photonic Imaging Group, MIRA Institute, University of Twente; AE Enschede The Netherlands
| | - Frauke Alves
- Institute of Interventional and Diagnostic Radiology, University Medical Center Göttingen; Göttingen Lower Saxony Germany
- Clinic of Haematology and Medical Oncology; University Medical Center Göttingen; Göttingen Lower Saxony Germany
- Translational Molecular Imaging, Max-Planck-Institute of Experimental Medicine; Göttingen Lower Saxony Germany
| |
Collapse
|
17
|
McNally LR, Mezera M, Morgan DE, Frederick PJ, Yang ES, Eltoum IE, Grizzle WE. Current and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in Oncology. Clin Cancer Res 2016; 22:3432-9. [PMID: 27208064 PMCID: PMC5046137 DOI: 10.1158/1078-0432.ccr-16-0573] [Citation(s) in RCA: 75] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 05/13/2016] [Indexed: 01/18/2023]
Abstract
Accurate detection and characterization of cancers are key for providing timely intervention and effective treatments. Current imaging technologies are particularly limited when it comes to detecting very small tumors in vivo, i.e., very early cancers or metastases, differentiating viable tumor from surrounding dead tumor tissue, and evaluating tumor metabolism within tissue. Optoacoustic imaging offers potential solutions to these imaging problems because of its ability to image optical absorption properties of both intrinsic tissue chromophores and exogenous contrast agents without the involvement of ionizing radiation. Optoacoustic imaging uses pulsed laser to induce localized thermoelastic expansion that generates acoustic waves detectable by an ultrasound transducer. To date, multispectral optoacoustic tomography (MSOT) has primarily been used in preclinical research; however, its use in translational and clinical research is expanding. This review focuses on current and emerging applications of optoacoustic imaging for molecular imaging of cancer using both exogenous and endogenous contrast agents and sheds light on potential future clinical applications. Clin Cancer Res; 22(14); 3432-9. ©2016 AACR.
Collapse
Affiliation(s)
- Lacey R McNally
- Department of Medicine, University of Louisville, Louisville, Kentucky.
| | - Megan Mezera
- Department of Radiation Oncology, University of Louisville, Louisville, Kentucky
| | - Desiree E Morgan
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama
| | - Peter J Frederick
- Department of Gynecology Oncology, Roswell Park Cancer Institute, Buffalo, New York
| | - Eddy S Yang
- Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama
| | - Isam-Eldin Eltoum
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
| | - William E Grizzle
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
| |
Collapse
|
18
|
Development of Drugs and Technology for Radiation Theragnosis. NUCLEAR ENGINEERING AND TECHNOLOGY 2016. [DOI: 10.1016/j.net.2016.04.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
19
|
Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography. J Control Release 2016; 231:60-7. [PMID: 26763377 DOI: 10.1016/j.jconrel.2015.12.055] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 12/23/2015] [Accepted: 12/30/2015] [Indexed: 01/26/2023]
Abstract
Despite significant efforts to translate nanotechnology for cancer application, lack of identification of biodistribution/accumulation of these nanovehicles in vivo remains a substantial barrier for successful implementation of theranostic nanoparticles in the clinic. The purpose of the study was to develop a tumor-targeted theranostic nanovehicle for pancreatic cancer detectable by multispectral optoacoustic tomography (MSOT). To improve the tumor specificity of our mesoporous silica nanoparticle (MSN), we utilized a dual targeting strategy: 1) an elevated tumor receptor, urokinase plasminogen activator receptor (UPAR), and 2) the acidic tumor microenvironment. The tumor specificity of the MSN particle was improved with the addition of both chitosan, targeting acidic pH, and urokinase plasminogen activator (UPA), targeting UPAR. Drug release assays confirmed pH responsive release of gemcitabine in vitro. The UPAR specific binding of MSN-UPA nanoparticles was confirmed by reduction in fluorescence signal following MSN-UPA nanoparticle treatment in UPAR positive cells blocked with a UPAR-blocking antibody. Based upon Indocyanine Green encapsulation within the nanoparticles, UPA ligand targeted MSNs demonstrated increased intensity compared to untargeted MSNs at both pH7.4 (7×) and 6.5 (20×); however the signal was much more pronounced at a pH of 6.5 using tissue phantoms (p<0.05). In vivo, MSN-UPA particles demonstrated orthotopic pancreatic tumor specific accumulation compared to liver or kidney as identified using multispectral optoacoustic tomography (p<0.05) and confirmed by ex vivo analysis. By tracking in vivo nanoparticle biodistribution with MSOT, it was shown that pH responsive, ligand targeted MSNs preferentially bind to pancreatic tumors for payload delivery.
Collapse
|